Table 6. Clinical Status and Follow-up... | American Society of Hematology

Table 6.

Clinical Status and Follow-up

Patients	Duration of Chronic Phase After ABMT (mo)	Duration of Survival After ABMT (mo)	Therapy After ABMT	Disease Phase	Total Survival From Diagnosis (mo)
1	21	44+	None after ABMT high-dose therapy for second BC	Third BC	50+
2	39	39	IFN-α/HU	death	72
3	7	7	—	death	42
4	30+	30	—	death in second CP	48
5	21	29	HU	death	74
6	26+	26+	IFN-α	second CP	48+
7	20+	20+	IFN-α	second CP	54+
8	14+	14+	IFN-α	second CP	86+

Patients	Duration of Chronic Phase After ABMT (mo)	Duration of Survival After ABMT (mo)	Therapy After ABMT	Disease Phase	Total Survival From Diagnosis (mo)
1	21	44+	None after ABMT high-dose therapy for second BC	Third BC	50+
2	39	39	IFN-α/HU	death	72
3	7	7	—	death	42
4	30+	30	—	death in second CP	48
5	21	29	HU	death	74
6	26+	26+	IFN-α	second CP	48+
7	20+	20+	IFN-α	second CP	54+
8	14+	14+	IFN-α	second CP	86+

Abbreviations: BC, blast crisis; HU, hydroxyurea; CP, chronic phase.